The reasons behind the disappointing outcomes from these clinical trials may include insensitivity of anti-VEGF therapy towards tumor blood vessels42 and alternative angiogenic growth factor expression43, highlighting the importance of identifying new angiogenic factors to be targeted. The gene discussed is VEGFA; the disease is neoplasm.